NASDAQ:CAPR - Capricor Therapeutics Stock Price, Price Target & More

Get Started

$1.38 +0.02 (+1.47 %)

(As of 05/20/2018 01:51 PM ET)

Previous Close$1.38

Today's Range$1.35 - $1.39

52-Week Range$0.63 - $4.25

Volume165,614 shs

Average Volume158,481 shs

Market Capitalization$40.17 million

P/E RatioN/A

Dividend YieldN/A

Beta-3.27

About Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CAPR

CUSIPN/A

Webwww.capricor.com

Phone310-358-3200

Debt

Debt-to-Equity RatioN/A

Current Ratio9.94

Quick Ratio9.41

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.67 million

Price / Sales15.05

Cash FlowN/A

Price / CashN/A

Book Value$0.36 per share

Price / Book3.83

Profitability

EPS (Most Recent Fiscal Year)($0.44)

Net Income$2.43 million

Net Margins110.98%

Return on Equity-485.43%

Return on Assets-85.83%

Miscellaneous

Employees40

Outstanding Shares29,110,000

Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) posted its quarterly earnings data on Wednesday, March, 14th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.01. The biotechnology company earned $0.48 million during the quarter, compared to the consensus estimate of $0.63 million. Capricor Therapeutics had a negative return on equity of 485.43% and a net margin of 110.98%. View Capricor Therapeutics' Earnings History.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Capricor Therapeutics.

What price target have analysts set for CAPR?

3 analysts have issued 1 year price objectives for Capricor Therapeutics' stock. Their predictions range from $2.15 to $9.00. On average, they anticipate Capricor Therapeutics' share price to reach $6.05 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.

Who are some of Capricor Therapeutics' key competitors?

Some companies that are related to Capricor Therapeutics include Eleven Biotherapeutics (EBIO), Adamis Pharmaceuticals (ADMP), Affimed (AFMD), Intec Pharma (NTEC), Teligent (TLGT), XBiotech (XBIT), AcelRx Pharmaceuticals (ACRX), RedHill Biopharma (RDHL), Otonomy (OTIC), Acer Therapeutics (ACER), Genprex (GNPX), Axovant Sciences (AXON), Zynerba Pharmaceuticals (ZYNE), Bellerophon Therapeutics (BLPH) and Alpine Immune Sciences (ALPN).

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the folowing people:

Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
Deborah Ascheim M.D., Chief Medical Officer
Joshua A. Kazam, Director (Age 40)

Has Capricor Therapeutics been receiving favorable news coverage?

Press coverage about CAPR stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Capricor Therapeutics earned a media sentiment score of 0.01 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.81 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $1.38.

How big of a company is Capricor Therapeutics?

Capricor Therapeutics has a market capitalization of $40.17 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]

MarketBeat Community Rating for Capricor Therapeutics (CAPR)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		144 (Vote Outperform)
Underperform Votes:		164 (Vote Underperform)
Total Votes:		308

MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Capricor Therapeutics (NASDAQ:CAPR) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Capricor Therapeutics in the last 12 months. Their average twelve-month price target is $6.05, suggesting that the stock has a possible upside of 338.41%. The high price target for CAPR is $9.00 and the low price target for CAPR is $2.15. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$6.05	$5.5750	$5.3750	$4.3250
Price Target Upside:	338.41% upside	335.55% upside	218.05% upside	336.87% upside

Capricor Therapeutics (NASDAQ:CAPR) Consensus Price Target History

Price Target History for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/16/2018	Maxim Group	Initiated Coverage	Buy	$7.00	High
5/11/2018	HC Wainwright	Reiterated Rating	Buy	$9.00	Medium
7/22/2017	Rodman & Renshaw	Reiterated Rating	Buy	$2.15	N/A
10/20/2016	Roth Capital	Set Price Target	Buy	$12.00	N/A

(Data available from 5/20/2016 forward)

Capricor Therapeutics (NASDAQ:CAPR) Earnings History and Estimates Chart

Earnings by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.48 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Capricor Therapeutics (NASDAQ CAPR) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/8/2018		($0.12)					N/A
3/14/2018	Q4 2017	($0.10)	($0.11)	$0.63 million	$0.48 million	View	Listen
11/8/2017	Q3 2017	($0.19)	($0.12)	$1.00 million	$0.31 million	View	N/A
8/10/2017	Q2 2017	($0.18)	($0.16)	$1.10 million	$1.00 million	View	N/A
5/15/2017	Q1 2017	($0.15)	($0.17)	$0.87 million	$0.88 million	View	N/A
3/15/2017	Q4 2016	($0.30)	($0.14)	$1.05 million	$0.91 million	View	N/A
11/10/2016	Q316	($0.27)	($0.29)	$1.12 million	$0.75 million	View	N/A
8/15/2016	Q2	($0.24)	($0.26)	$1.22 million	$1.13 million	View	Listen
5/12/2016	Q116	($0.19)	($0.26)	$1.10 million	$1.22 million	View	Listen
3/17/2016	Q415	($0.19)	($0.21)	$1.10 million	$1.12 million	View	N/A
11/12/2015	Q315	($0.26)	($0.18)	$1.10 million	$1.32 million	View	N/A
8/13/2015	Q215	($0.26)	($0.19)	$1.10 million	$1.29 million	View	N/A
5/12/2015	Q1 2015	($0.14)	($0.23)	$1.10 million	$1.79 million	View	N/A
3/18/2015	Q4 2014	($0.14)	($0.16)	$1.30 million	$1.40 million	View	N/A
11/13/2014	Q3 2014	($0.22)	($0.13)		$1.30 million	View	N/A
8/14/2014	Q2 2014		($0.13)		$1.04 million	View	N/A
5/15/2014	Q1 2014		($0.10)		$1.04 million	View	N/A
8/14/2013	Q2 2013		($0.50)			View	N/A
6/21/2013	Q4 2012		($11.50)			View	N/A
8/14/2012	Q2 2012	($1.00)	($0.40)			View	N/A
5/15/2012	Q1 2012	($1.00)	($0.95)			View	N/A
11/14/2011	Q3 2011	($1.00)	($1.45)			View	N/A
8/15/2011	Q2 2011	($1.00)	($1.25)			View	N/A
5/16/2011	Q1 2011	($1.00)	($1.70)			View	N/A
3/14/2011	Q4 2010	($2.00)	($1.15)			View	N/A
11/12/2010	Q3 2010	($2.50)	($2.60)			View	N/A
8/16/2010	Q2 2010	($3.50)	($2.30)			View	N/A
5/14/2010	Q1 2010	($3.00)	($3.50)			View	N/A
3/3/2010	Q4 2009	($2.50)	($2.90)			View	N/A
11/12/2009	Q3 2009	($2.50)	($4.00)			View	N/A
8/13/2009	Q2 2009	($3.50)	($5.20)			View	N/A
5/14/2009	Q1 2009	($6.00)	($3.70)			View	N/A
3/9/2009	Q4 2008	($7.00)	($6.15)			View	N/A
11/13/2008	Q3 2008	($8.00)	($6.90)			View	N/A
8/14/2008	Q2 2008		($7.85)			View	N/A
5/15/2008	Q1 2008		($6.35)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Capricor Therapeutics (NASDAQ:CAPR) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Capricor Therapeutics (NASDAQ CAPR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.00%
Institutional Ownership Percentage: 8.58%

Insider Trading History for Capricor Therapeutics (NASDAQ:CAPR)

Institutional Ownership by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ CAPR) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/9/2017	Louis Manzo	Director	Buy	10,000	$3.10	$31,000.00	138,384
5/9/2017	Sinai Medical Center Cedars	Major Shareholder	Buy	1,145,161	$3.10	$3,549,999.10	4,049,959
9/21/2016	Sinai Medical Center Cedars	Major Shareholder	Buy	312,500	$3.20	$1,000,000.00	2,904,798
3/16/2016	Anthony Bergmann	VP	Buy	2,030	$2.40	$4,872.00	2,030
3/16/2016	Karen Krasney	EVP	Buy	4,060	$2.40	$9,744.00	11,156
3/16/2016	Leland Gershell	CFO	Buy	2,100	$2.40	$5,040.00	2,100
3/16/2016	Linda Marban	CEO	Buy	10,152	$2.40	$24,364.80
3/16/2016	Louis J Grasmick	Director	Buy	91,369	$2.40	$219,285.60
3/16/2016	Sinai Medical Center Cedars	Major Shareholder	Buy	416,666	$2.40	$999,998.40	2,592,298
8/20/2015	Louis J. Grasmick	Director	Buy	11,900	$4.11	$48,909.00	5,950
8/19/2015	Eduardo Marban	major shareholder	Buy	18,400	$4.36	$80,224.00	3,173,354
1/21/2015	Joshua A Kazam	Director	Buy	7,096	$3.52	$24,977.92
1/21/2015	Sinai Medical Center Cedars	Major Shareholder	Buy	851,546	$3.52	$2,997,441.92

(Data available from 1/1/2013 forward)

Capricor Therapeutics (NASDAQ CAPR) News Headlines

Source:

Date	Headline
	Benzinga's Top Upgrades, Downgrades For May 16, 2018 www.benzinga.com - May 17 at 8:21 AM
	UPDATE: Maxim Group Starts Capricor Therapeutics (CAPR) at Buy www.streetinsider.com - May 17 at 8:21 AM
	Capricor Therapeutics (CAPR) Research Coverage Started at Maxim Group www.americanbankingnews.com - May 16 at 3:23 PM
	How Did Capricor Therapeutics Inc’s (NASDAQ:CAPR) 23.03% ROE Fare Against The Industry? finance.yahoo.com - May 16 at 8:19 AM
	Form 10-Q CAPRICOR THERAPEUTICS, For: Mar 31 www.streetinsider.com - May 15 at 5:49 PM
	Capricor Therapeutics (CAPR) Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - May 11 at 6:49 PM
	Capricor Therapeutics (CAPR) Rating Reiterated by HC Wainwright www.americanbankingnews.com - May 11 at 5:49 PM
	Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 11 at 8:27 AM
	Capricor Therapeutics misses by $0.02, misses on revenue seekingalpha.com - May 10 at 5:57 PM
	Capricor: 1Q Earnings Snapshot finance.yahoo.com - May 10 at 5:57 PM
	Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update finance.yahoo.com - May 10 at 5:57 PM
	Capricor Therapeutics (CAPR) to Release Earnings on Monday www.americanbankingnews.com - May 7 at 3:28 AM
	Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10 finance.yahoo.com - May 4 at 8:18 AM
	ValuEngine Upgrades Capricor Therapeutics (CAPR) to Sell www.americanbankingnews.com - May 3 at 10:05 PM
	Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal finance.yahoo.com - May 3 at 8:16 AM
	Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy finance.yahoo.com - April 30 at 8:24 AM
	Wired News – Capricor’s New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy finance.yahoo.com - April 23 at 8:15 AM
	Findings are the Basis for the HOPE-2 Clinical Trial globenewswire.com - April 19 at 8:16 AM
	Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model finance.yahoo.com - April 19 at 8:16 AM
	Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day globenewswire.com - April 12 at 8:35 AM
	Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day finance.yahoo.com - April 12 at 8:35 AM
	Capricor Therapeutics (CAPR) Upgraded by ValuEngine to "Sell" www.americanbankingnews.com - April 8 at 1:28 PM
	Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018 finance.yahoo.com - April 6 at 5:41 PM
	Capricor Therapeutics (CAPR) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 4 at 6:54 PM
	Capricor Therapeutics (CAPR) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow seekingalpha.com - March 29 at 5:30 PM
	Capricor Therapeutics (CAPR) PT Set at $9.00 by HC Wainwright www.americanbankingnews.com - March 29 at 11:16 AM
	Capricor Therapeutics (CAPR) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - March 28 at 7:04 PM
	Wired News – OPKO Health Announced Enrollment of First Patient in Phase-2b Trial of OPK88003 to Treat Type-2 Diabetes finance.yahoo.com - March 27 at 8:27 AM
	Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences - GlobeNewswire (press release) globenewswire.com - March 21 at 8:48 AM
	Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences finance.yahoo.com - March 21 at 8:48 AM
	Capricor Therapeutics (CAPR) versus Versartis (VSAR) Critical Contrast www.americanbankingnews.com - March 16 at 5:22 AM
	Capricor Therapeutics (CAPR) Posts Earnings Results, Misses Estimates By $0.01 EPS www.americanbankingnews.com - March 15 at 10:45 AM
	Capricor Therapeutics, Inc. to Host Earnings Call finance.yahoo.com - March 14 at 7:07 PM
	Has Capricor Therapeutics Inc (NASDAQ:CAPR) Improved Earnings Growth In Recent Times? finance.yahoo.com - March 14 at 7:07 PM
	Earnings Preview For Capricor Therapeutics finance.yahoo.com - March 14 at 7:07 PM
	Capricor posts 4Q profit finance.yahoo.com - March 14 at 7:07 PM
	Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update finance.yahoo.com - March 14 at 7:07 PM
	Capricor Therapeutics (CAPR) Upgraded to "Buy" by Zacks Investment Research www.americanbankingnews.com - March 12 at 7:10 PM
	Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on ... - GlobeNewswire (press release) globenewswire.com - March 9 at 8:20 AM
	Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14 finance.yahoo.com - March 8 at 6:44 PM
	Capricor Therapeutics (CAPR) Cut to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 7 at 6:57 PM
	Capricor Therapeutics (CAPR) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - March 6 at 7:00 PM
	Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - March 6 at 2:32 AM
	Brown Advisory Inc. Buys New Stake in Capricor Therapeutics Inc (CAPR) www.americanbankingnews.com - March 2 at 5:10 AM
	Capricor to Host Key Opinion Leader Lunch on March 9 - GlobeNewswire (press release) globenewswire.com - March 1 at 8:15 AM
	Capricor to Host Key Opinion Leader Lunch on March 9 finance.yahoo.com - February 28 at 8:17 AM
	Report: Developing Opportunities within Tupperware Brands, Eaton Vance, Marcus & Millichap, Lockheed Martin, Coherus BioSciences, and Capricor Therapeutics — Future Expectations, Projections Moving into 2018 finance.yahoo.com - February 23 at 8:21 AM
	New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy finance.yahoo.com - February 22 at 5:38 PM
	Capricor Therapeutics (CAPR) Lowered to "Hold" at Zacks Investment Research www.americanbankingnews.com - February 14 at 7:12 PM
	Capricor Therapeutics (CAPR) Upgraded at Zacks Investment Research www.americanbankingnews.com - February 13 at 7:00 PM

Capricor Therapeutics (NASDAQ:CAPR) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Capricor Therapeutics (NASDAQ:CAPR) Income Statement, Balance Sheet and Cash Flow Statement

Capricor Therapeutics (NASDAQ CAPR) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff